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Background: Most microdeletions involving chromosome sub-bands 9q33.3-9q34.11 to this point have been
detected by analyses focused on STXBP1, a gene known to cause early infantile epileptic encephalopathy 4 and
other seizure phenotypes. Loss-of-function mutations of STXBP1 have also been identified in some patients with
intellectual disability without epilepsy. Consequently, STXBP1 is widely assumed to be the gene causing both
seizures and intellectual disability in patients with 9q33.3-q34.11 microdeletions.
Results: We report five patients with overlapping microdeletions of chromosome 9q33.3-q34.11, four of them previously
unreported. Their common clinical features include intellectual disability, psychomotor developmental delay with delayed
or absent speech, muscular hypotonia, and strabismus. Microcephaly and short stature are each present in four of the
patients. Two of the patients had seizures. De novo deletions range from 1.23 to 4.13 Mb, whereas the smallest deletion of
432 kb in patient 3 was inherited from her mother who is reported to have mild intellectual disability. The smallest region
of overlap (SRO) of these deletions in 9q33.3 does not encompass STXBP1, but includes two genes that have not been
previously associated with disease, RALGPS1 and GARNL3.
Sequencing of the two SRO genes RALGPS1 and GARNL3 in at least 156 unrelated patients with mild to severe idiopathic
intellectual disability detected no causative mutations. Gene expression analyses in our patients demonstrated
significantly reduced expression levels of GARNL3, RALGPS1 and STXBP1 only in patients with deletions of the
corresponding genes. Thus, reduced expression of STXBP1 was ruled out as a cause for seizures in our patient
whose deletion did not encompass STXBP1.
Conclusions: We suggest that microdeletions of this region on chromosome 9q cause a clinical spectrum
including intellectual disability, developmental delay especially concerning speech, microcephaly, short stature,
mild dysmorphisms, strabismus, and seizures of incomplete penetrance, and may constitute a new contiguous
gene deletion syndrome which cannot completely be explained by deletion of STXBP1.
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Previously, microdeletions affecting the chromosomal
region 9q33.3-q34.11 have been reported in association
with early infantile epileptic encephalopathy 4 (EIEE4, or
Ohtahara syndrome, OMIM #612164). The STXBP1
gene was identified as a causative gene and loss-of-
function mutations of STXBP1 have been shown to
cause EIEE4 [1], West syndrome [2], other seizure phe-
notypes [3], non-syndromic epilepsy [4], and intellectual
disability (ID). De novo sequence mutations in STXBP1
have also been reported to be associated with ID without
epilepsy [5].
Here we present the clinical and genetic characterization
of five patients whose common clinical features include
intellectual disability (ID), psychomotor developmental
delay (DD) with delayed or absent speech, muscular
hypotonia, strabismus, dysmorphisms and other recurrent
findings. For these patients, we have identified overlapping
microdeletions of chromosome 9q33.3-q34.11 by molecu-
lar karyotyping. The smallest region of overlap (SRO)
concerning these common clinical features contains only
two RefSeq genes, which has implications regarding the





Patient 1 is the first and only child of healthy non-
consanguineous parents from Turkey with unremarkable
family histories. She was born by vacuum extraction
after 41 weeks of gestation with a birth weight of 3135 g
(10–25th centile, −1.1 S.D.), a length of 49 cm (3rd–10th
centile, −1.7 S.D.), and an OFC of 32 cm (<3rd centile,
−2.6 S.D.). Postnatal adaptation was normal (APGAR
10/10, umbilical cord pH 7.26). Exotropia of the left eye
and bilateral pes supinatus were noted at the age of
1 month. Between 6 and 10 months of age, she displayed
clear motor delays and muscular hypotonia. Cranial
ultrasound examination at 8 months gave normal results,
except for asymmetry of lateral ventricles. Hearing was
normal.
At the age of 10 months, her height and weight were
normal [69 cm (3rd–10th centile, −1.6 S.D.); 10.5 kg
(90–97th centile, +1.6 S.D.)], but she remained micro-
cephalic [42.7 cm (<3rd centile, −2.3 S.D.)]. Clinical genetic
examination at 11 months revealed some craniofacial dys-
morphism with cranial asymmetry (flat right occiput),
round face, telecanthus, upslanting palpebral fissures,
epicanthic folds, short nose, thin upper lip, low-set ears
with attached earlobes, and a short neck. Her fingers were
tapered with ridges of both thumb and index finger nails
(Fig. 1a, c). Pes equinus was noted. She showed muscular
hypotonia, especially of the trunk and shoulder girdle. Shewas able to bring her hands together as well as to her
mouth and feet, as well as grasp toys and transfer them to
the opposite side of her body. However, she was unable to
roll over or support her upper body in the prone position.
At the age of 20 months she weighed 14 kg (97th centile,
+2.0 S.D.), her height was 78.5 cm (3rd–10th centile,
−1.8 S.D.), and her OFC was 46 cm (10–25th centile,
−1.1 S.D.). In addition to the craniofacial dysmorphism
described above she showed brachycephaly and a high
frontal hairline. At the age of 20 months she was able to
roll over but not to crawl. Language development was
delayed with only few syllables. She showed strabismus
and bruxism. Recurrent otitis was treated with transtym-
panic drains. The parents reported that EEG and ultra-
sonic examinations of the heart and kidneys were
performed with normal results. Cerebral MRI scan at the
age of 33 months showed a delay of myelination of about
3 months. At the age of 3 years, muscular hypotonia was
very distinctive. The patient was unable to sit, stand, or
walk. Her parents reported lack of pain sensation. She still
displayed no seizures.
Conventional karyotyping and sequencing of the
RPS6KA3 (RSK2) gene yielded normal results.
Patient 2
Patient 2 is the first child of healthy and unrelated par-
ents. He was delivered spontaneously after gestational
week 40 + 4 with a birth weight of 2650 g (<3rd centile,
−2.3 S.D.), a length of 47 cm (<3rd centile, −2.5 S.D.),
and an OFC of 31.5 cm (<3rd centile, −3.3 S.D.). Global
developmental delay became apparent at 1 year. At
15 months he was able to turn from supine to prone.
Clinical features including ataxia, repeatedly pathological
EEG, and a cheerful manner suggested Angelman syn-
drome. No speech development was apparent. At the
age of 5 years, he was able to crawl and to walk with
assistance. His weight was 15 kg (<3rd centile, −2.1 S.D.),
his height 97 cm (<3rd centile, −3.1 S.D.), and his head
circumference 48 cm (<3rd centile, −2.9 S.D.). He showed
slight dysmorphisms such as a prominent forehead, arched
eyebrows, slightly upslanting palpebral fissures, smooth
philtrum, thin upper lip, and widely-spaced teeth, but no
major dysmorphic stigmata (Fig. 1d).
Conventional karyotyping, subtelomere screening, methy-
lation analysis at the 15q11.2 locus, and sequencing of
UBE3A and SLC9A6 gave normal results.
Patient 3
Patient 3 is a 6-year-old girl born as the first child of a
French mother and an unknown father. Her 3-year-old
maternal half-brother shows normal development. The
mother, who was 15 years old at the birth of her daugh-
ter, has mild intellectual disability and poor language
abilities. She has normal measurements without micro-
Fig. 1 Facial phenotypes and nail abnormalities of patients with 9q33.3-q34.1 deletion. Facial phenotypes of patients 1–5 (a, b and d-l) and nail
abnormalities of patient 1 (c). Patient 1 at the age of 11 months (a) and 35 months (b). Note round face, telecanthus, upslanting palpebral fissures,
epicanthic folds, short nose, thin upper lip, low-set ears, tapering fingers, and ridged nail of the thumb (c). Patient 2 at the age of 5 years (d), and 6 years
(e, f). Note prominent forehead, arched eyebrows, slightly upslanting palpebral fissures, and thin upper lip. Patient 3 at the age of 4 years (l). Note high
frontal hairline, a short nose with anteverted nares and a dimpled chin. Patient 4 at the age of 5 months (g), 3 years (h), and 5 years (i). Note high
frontal hairline, telecanthus, upslanting palpebral fissures, arched eyebrows, and thin upper lip. Patient 5 at the age of 11 years (j, k). Note round face,
thin upper lip, and prominent lower lip
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morphisms are mildly anteverted nares and a dimpled chin.
Patient 3 was born at gestational week 35 with a
weight of 2630 g (50th centile), a length of 45 cm (25th
centile, −1.0 S.D.), and an OFC of 31 cm (10th centile,
−1.5 S.D.). Mild muscular hypotonia was noted as wellas talus valgus. She started walking at the age of
14 months and walked without support at 22 months.
Neither feeding difficulties nor obesity were reported in
the first 2 years of life. There was no active speech
development. Her recurrent otitis was treated repeatedly
with transtympanic drains.
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and 5 months, her weight was 13 kg (3rd centile,
−2.0 S.D.), her height was 92 cm (3rd centile, −2.0 S.D.),
and her OFC was 45.5 cm (3rd centile, −2.0 S.D.). She
was microcephalic but not brachycephalic. A high
frontal hairline, convergent strabismus, a short nose with
anteverted nares and a dimpled chin were noted (Fig. 1l).
Hands and fingers were normal. Language development
was severely delayed with only few syllables and cries as
vocalizations. She showed stereotypic hand movements
and autistiform behavior. She suffered from seizures
which were treated with Valproate. A cerebral MRI scan
showed bilateral temporal-occipital pachygyria with het-
erogeneous “nodules” of grey cortex. Upon examination at
the age of 6 years, her weight was 19.4 kg (25th centile,
−0.5 S.D.), her height was 105 cm (3rd centile, −2.0 S.D.),
and her OFC remained at 48 cm (3rd centile, −2.0 S.D.).
Severe intellectual disability, muscular hypotonia, and aut-
istic behavior were still present. She showed bruxism and
her language was limited to repeating single words. She
had strabismus, a short nose with anteverted nares, and a
flat face, as well as long and thin fingers and pes planus.
At the age of 9 years, she was still reported to have no
active speech and to have remained seizure-free under
treatment for 20 months.
FMR1 analyses by PCR and Southern blot and MECP2
analysis (DHPLC) gave normal results.
Patient 4
Patient 4 is a 5 year and 6 months old girl born prema-
turely after 27 weeks of gestation because of a placental
hematoma. Her unrelated parents are of French descent
and there is no particular familial history of genetic dis-
ease. Birth weight was 950 g (65th centile, +0.5 S.D., age-
corrected), height was 34 cm (37th centile, −0.5 S.D.),
and OFC 24 cm (29th centile, −0.5 S.D.). Bilateral talipes
equinus and a patent ductus arteriosus which required
surgical treatment were noted at birth. She had retinop-
athy of prematurity with vitreous hemorrhage as well as
bilateral microphtalmia and alternate strabismus. At the
age of 2 months, she presented with generalized seizures
with persistent, almost daily crises which were resistant to
treatment. A brain MRI gave normal results. Arm and
forearm X-rays showed diffuse bone demineralization and
radiocubital synostosis.
She was first referred for clinical genetic evaluation at
the age of 5 months. Dysmorphic features including high
frontal hairline, telecanthus, upslanting palpebral fis-
sures, arched eyebrows, flat nasal bridge, thin upper lip,
and retrognathism were noted (Fig. 1g). She also had
bilateral 5th finger clinodactyly, absent thumb nails, and
arched and abnormal nails of both index fingers. Her
weight was 3625 g (5th centile, −1.9 S.D., age-corrected),
height 49.5 cm (1st centile, −2.5 S.D., age-corrected), andOFC 35 cm (<3rd centile, −3.2 S.D.). Standard karyotyp-
ing gave normal results. At last examination at the age
of 5 years and 6 months (Fig. 1i), she still had developed
no active language but showed eye contact and was able
to smile. Sitting without support had not been acquired.
Her weight was 16 kg (8th centile, −1.8 S.D.), height
96 cm (below the 1st centile, −3.5 S.D.), and her OFC
47 cm (2nd centile, −2.2 S.D.). Nephropathy was diag-
nosed and CT scans at the age of 5 years and 6 months
showed non-ossified and dislocated patellae, with bilat-
eral patellar tendon hypoplasia.Patient 5
Patient 5 was published previously without clinical detail
[6]. She was the first child to non-consanguineous
healthy Brazilian-Swiss parents after eight miscarriages
and two unsuccessful IVF attempts. The family history
was otherwise unremarkable. After an uneventful preg-
nancy, the girl was born at term by Cesarean section. At
birth, her weight was 2500 g (3rd–10th centile, −2.0 S.D.)
and her length 48 cm (25–50th centile, −1.2 S.D.); her
head circumference was not documented.
As a neonate she presented with muscular hypotonia
and subsequently with pronounced early developmental
delay. She started sitting without support at 1 year of
age and started walking at 4 years of age. She developed
truncal and gait ataxia. Cerebral MRI and EEG exams at
6 years of age gave normal results. She never presented
with clinical seizures. Sleeping issues were apparent,
including trouble in falling asleep or to sleep through
the night, and parasomnia with episodes of crying and
screaming. Polysomnography at 10 years of age did not
show EEG anomalies but confirmed episodes of arousal
and pavor nocturnus. At the age of 11 years and
7 months, she spoke a few words. Auditory testing was
normal. Except for strabismus, there were no visual
impairments. Celiac disease was confirmed by biopsy
and treated by diet. Toilet training has never been
achieved.
At 11 years and 7 months of age, the patient presented
with truncal obesity (OFC 53 cm, 25–50th centile,
−1.2 S.D.; length 137 cm, 10th centile, −1.5 S.D.; weight
44 kg, 50–75th centile, +0.6 S.D.). She was restless and
hyperactive, limiting the overall physical exam. She did
not have specific dysmorphic signs; a round face, round
eyes with long eyelashes, strabismus, a short nose, a thin
upper lip, and an everted lower lip were noted (Fig. 1j, k).
Hands and feet were small with pes planus. Hypotonia
and ataxia were evident.
Previous genetic testing for Angelman syndrome
(methylation specific PCR) and karyotype analysis as
well as standard metabolic testing results gave nor-
mal results.
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In patients 1, 2, 4 and 5, de novo deletions in 9q33.3-q34.11
ranging from 1.23 to 4.13 Mb were detected using various
array platforms (Table 1, Fig. 2). Interestingly, the smallest
deletion was detected in patient 3, whose 432-kb deletion
was inherited from her mother who is reported to have
mild ID. The smallest region of overlap (SRO) is defined by
the distal boundary of the deletion in patient 3 and the
proximal deletion boundary in patient 5, and includes only
two RefSeq genes, RALGPS1 and GARNL3. In patients 1, 2,
3 and 4, ANGPTL2 is also deleted. Importantly, the SRO
does not include the STXBP1 gene in 9q34.11 (Fig. 2). No
additional de novo CNVs or CNVs in known copy number-
sensitive regions have been detected.Sanger sequencing of SRO genes RALGPS1 and GARNL3
Every exon including exon/intron boundaries of all known
protein-coding RefSeq isoforms of GARNL3 and RALGPS1
has been studied in at least 156 of the 192 ID/DD patients.
The sequencing revealed eight rare variants in GARNL3
and none in RALGPS1 (Additional file 1: Table S1). All
GARNL3 variants were present in a heterozygous state in
either one or two patients with ID/DD (minor allele
frequencies/MAF < 0.58 %). Four variants caused amino
acid changes whereas the remaining four variants were syn-
onymous. In total, four of the eight GARNL3 variants were
listed in dbSNP build 134 and were also present in the
NHLBI GO-ESP cohort (Exome Variant Server, NHLBI GO
Exome Sequencing Project (ESP), http://evs.gs.washington.
edu/EVS/; July 2015). The remaining four variants were
followed up by pedigree analyses. All variants had been
inherited from an unaffected parent (Additional file 1:
Table S1), suggesting no obvious association between
the variants and the occurrence of ID.Expression analyses of SRO genes and STXBP1
We performed gene expression studies with prede-
signed Taqman gene expression assays for GARNL3,
RALGPS1, STXBP1, and ANGPTL2 on whole blood
RNA of five patients with microdeletion and of five un-
affected control persons. The expression level of
ANGPTL2 which is not contained in the SRO but in
four of the detected microdeletions including the smal-
lest one was determined to be too low in whole blood
RNA to obtain results.
Compared to the mean of five unaffected controls, the
expression levels of GARNL3 were significantly (p <
0.05) reduced in all five patients (Fig. 3a). For RALGPS1,
the expression was reduced significantly in patients 1
through 4, but not in patient 5 (Fig. 3b). STXBP1
showed a significantly reduced expression in patients 1,
2, and 4, while its expression in patients 3 and 5 was not
reduced significantly (Fig. 3c).Discussion
Array CGH is now widely used in cytogenetics centers
for postnatal constitutional genome analysis and in
research for the identification of new causative microde-
letion and microduplication syndromes or copy number
variations (CNVs) and has alos been instrumental in the
identification of new candidate genes for e.g. intellectual
disability (ID) [7–9].
Several microdeletions involving the chromosomal
region 9q33.3-q34.11 have been reported and seem to be
associated with a range of clinical phenotypes including,
but not limited to, ID, developmental delay (DD), and
seizures [10, 11]. Several studies identifying such micro-
deletions had in fact been focused on patients with
diverse seizure phenotypes [1, 12] or aimed at identifying
mutations including CNVs involving STXBP1. De novo
missense, nonsense, frameshift, and splice-site muta-
tions, as well as genomic deletions of STXBP1, have
been found in association with Early Infantile Epileptic
Encephalopathy 4 (EIEE4; OMIM #612164) and other
epilepsy types [13], such that STXBP1 haploinsufficiency
is the accepted cause of these epileptic phenotypes. Con-
sequently, all the published microdeletions of 9q33.3-
q34.11 contained STXBP1 and all published microdeletion
carriers suffered from seizures.
Here, we report five novel patients with microdeletions
of 9q33.3 only or 9q33.3-q34.11 which vary greatly in
size (0.4–4.1 Mb; Table 1) and gene content (3–95
RefSeq genes). The smallest deletion reported here
encompasses only three RefSeq genes (RALGPS1,
ANGPTL2, and GARNL3). In spite of the differences
between the breakpoints of their deletions, the patients
show considerable clinical similarities. All five patients
have ID and DD with pronounced speech delay or impair-
ment, muscular hypotonia, and strabismus. Microcephaly
and postnatal (borderline) short stature are present in four
of the patients, while only two of them display seizure
phenotypes. Other clinical findings shared by at least two
patients include ataxia phenotypes (patients 2 and 5),
recurrent otitis media (patients 1 and 3), and unspecific
brain MRI findings (patients 1, 2, and 3) including delayed
myelination in two patients. Common dysmorphisms in-
clude a round face (patients 1 and 5), upslanting palpebral
fissures (patients 1 and 2), a short nose (patients 1, 2, and
5), and a thin upper lip (patients 1, 2, and 5).
In addition, two of the patients reported here also dis-
play typical findings of Nail-Patella syndrome (NPS,
OMIM # 161200), including talipe equinus, reduced pain
sensation, high frontal hairline, and ridged nails in patient
1 (Fig. 1c) and bilateral 5th finger clinodactyly, missing
nails of the first fingers, talipe equinus, non-ossified and
dislocated patellae, and typical forearm malformations in
patient 3. However, the gene known to be responsible for
NPS, LMX1B, only appears to be deleted in patient 4,
Table 1 Main clinical findings in patients with microdeletions of 9q33.3-q34.1















Deletion size 1.76 Mb 1.20 Mb 432 kb 4.13 Mb 1.23 Mb 2.65 Mb 830 kb 2.10 Mb 2.85 Mb 3.3 Mb






























































































Origin De novo De novo Maternal De novo De novo De novo De novo De novo De novo De novo
Age 3 y 5 y 6 y 5 y, 6 mo 11 y, 7 mo 6 y 6 y 2 y, 11 mo 1 y, 7 mo 10 y
Sex Female Male Female Female Female male Male Female Male Female
Birth
parameters
Length <10th centile <3rd centile 25th centile 10th centile ND n.r. n.r. −2.3 SD Normal ~10th centile
(est.)
Weight 10th centile 3rd centile 50th centile 10th centile 0.4th–2nd
centile
n.r. n.r. −2.4 SD Normal ~10th centile
(est.)








3rd centile 0.4th centile n.r. n.r. <−2SDa n.r. 10th centile




2 cm < 3rd
centile
~0.5 cm < 3rd
centile




Microcephaly + + + – + + n.r.. n.r. + +
Intellectual
disability
+ + + + + + + + + +
Speech Delayed
(only syllables)
































Table 1 Main clinical findings in patients with microdeletions of 9q33.3-q34.1 (Continued)
Seizures – – + + – + – + + +





















































































































































Table 1 Main clinical findings in patients with microdeletions of 9q33.3-q34.1 (Continued)







































Summary of patient phenotypes and deletions
est. estimated, ND not determined, n.r. not reported, OFC occipitofrontal circumference, SD standard deviation, + present, – absent, y years, mo months











Fig. 2 Schematic representation of the microdeletions. Red bars: Microdeletions of patients 1 through 5 are presented. Grey bars: previously published
microdeletions. Lower panel: detail with smallest region of overlap (SRO, dashed lines, red box) and RefSeq genes with black arrows showing direction of
transcription (green: genes analyzed by expression studies)
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base pairs downstream from LMX1B. However, as the
deletion breakpoints have not been sequenced, it is possible
that the deletion in patient 1 in fact could extend into the
coding region of LMX1B, causing features of NPS.
A comparison of the clinical picture of the patients with
microdeletions reported here with published carriers of
STXBP1 loss-of-function point mutations or intragenic
deletions yields several similarities. ID and DD with lan-
guage delay, muscular hypotonia, seizures, ataxia, and
brain MRI findings including hypomyelination were also
present in patients with STXBP1 mutations [3–5, 14]. The
reduced penetrance regarding seizures reported by Ham-
dan and colleagues is confirmed and even emphasized by
our findings, since only one out of four carriers with
STXBP1-encompassing microdeletions reported here suf-
fered from seizures. In contrast to these commonalities,
several clinical findings are exclusively present in our pa-
tients with microdeletions. To our knowledge, microceph-
aly, short stature, and strabismus have not been reported
in carriers of STXBP1 point mutations or of deletionsaffecting STXBP1 only. This may also be true for at least
some of our patients’ dysmorphisms, but in most studies
of STXBP1 point mutations, the presence or absence of
dysmorphisms is not mentioned. Only Hamdan and col-
leagues explicitly state that there were no dysmorphic
features present in their three patients with truncating
STXBP1 mutations. Thus, it may be assumed that the com-
mon findings–microcephaly, short stature, and possibly
strabismus–which are exclusive to the five patients with
microdeletions reported here are unrelated to STXBP1 and
associated instead with the smallest region of overlap
(SRO) of their deletions. Importantly, our patient 3 presents
with seizures although her deletion does not include
STXBP1 and her STXBP1 expression is not reduced. We
thus hypothesize that her seizures are unrelated to STXBP1
and may instead be caused by the deletion of the SRO.
We are aware of five previously published patients
with microdeletions including these SRO genes (Table 1).
For three of these patients, seizures were the primary in-
dication for referral [1, 12, 13], while two of the patients
were referred for array CGH for a diverse set of clinical
Fig. 3 Results of expression analyses for a GARNL3, b RALGPS1, and c STXBP1. The mean expression of five unaffected controls is set to 1.0 (dark grey
bar). The expression level of the patients (light grey) is set in relation to the mean of the five controls. Error bars are based on the data obtained
over three experiments. Asterisks mark significant expression differences between patients and controls (p < 0.05, Wilcoxon-test)
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data displayed ID and DD with severe language delay
and muscular hypotonia. Eight out of nine patients had
postnatal microcephaly and five out of seven postnatal
short stature or borderline short stature. Seven out of
ten patients had brain MRI abnormalities and six out of
ten suffered from seizures. When excluding the three
patients investigated primarily because of their seizures,
to minimize any ascertainment bias, only three out of
seven patients suffered from seizures. Dysmorphisms are
present in most patients and some dysmorphic features
were seen in up to three of the patients presented here.
However, there does not seem to be a readily recognizable
dysmorphism pattern.
The SRO is localized in distal 9q33.3 and only includes
two RefSeq genes, RALGPS1 and GARNL3. In patients 1
through 4, the ANGPTL2 gene is also deleted (Fig. 2).
The clinical and genomic evidence may point to the
existence of a 9q33.3 microdeletion syndrome which
may be unrelated to STXBP1 haploinsufficiency. Until
now, none of the three genes has been associated with
disease. RALGPS1 (Ral GEF with PH domain and SH3
binding motif 1), formerly known as RalGEF2, encodes a
guanine nucleotide exchange factor or GEF for Ral (de
Bruyn et al. 2000 [15]). Ral (RalA and RalB) is a small
GTPase of the Ras family implicated in the control ofcell proliferation, differentiation, cytoskeletal organization,
and vesicular transport. One of the mechanisms of Ral
activation is the direct binding of active Ras to Ral-specific
GEFs such as RALGPS1 [15]. RALGPS1 expression is
rather ubiquitous with the highest expression levels in
brain, heart, kidney, adrenal gland, and colon. The evi-
dence for RALGPS1 haploinsufficiency is equivocal: the
Residual Variation Intolerance (RVI) score, which quan-
tifies gene intolerance to functional mutations [16] is
intermediate (−0.293801652, corresponding to the 32.9th
percentile). As a comparison, the average RVI score for
known developmental disorders is lower (0.56; 19.54th
percentile). On the other hand, its low haploinsufficiency
score (HI) of 8.9 % indicates a high probability for hap-
loinsufficiency being pathogenic [17].
Very little is known about the GARNL3 (Homo sapiens
GTPase activating Rap/RanGAP domain-like 3) gene. It
appears to be involved in the regulation of small GTPase-
mediated signal transduction and human GARNL3 is rather
ubiquitously expressed with the highest expression in brain
[18]. Rap/ran-GAP domains are found in GTPase activating
proteins (GAP) responsible for the activation of nuclear
Ras-related regulatory proteins Rap1, Rsr1 and Ran. Again,
the evidence for GARNL3 haploinsufficiency is equivocal
with a very low RVI score of −1.082044518 (7.2th percentile)
and a rather high haploinsufficiency score (HI) of 33.6 %.
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known as ARP2 for angiopoietin-related protein-2) is
discussed here although it is not contained in the SRO
because it is deleted in four out of five microdeletions
presented here, including the smallest one. It is a
secreted glycoprotein that has been implicated in angio-
genesis, inflammation, and atherosclerosis, as well as
enhancing the survival of human hematopoietic stem
cells [19]. It is a member of the Angiopoietin vascular
endothelial growth factor family and is largely specific
for vascular endothelium. Angptl2 is expressed in the
heart, adipose tissue, stomach, small intestine, colon,
ovary, uterus, spleen, striated muscle, and, at lower
levels, in other tissues and Angptl2 is secreted by differ-
ent cell types such as adipocytes, endothelial cells, mac-
rophages, keratinocytes and cancer cells [19, 20]. In
zebrafish embryos, Zangptl2 expression was detected in
the yolk sac extension and in posterior spinal cord dur-
ing early development and shown to diminish gradually
as development proceeded [21]. During chick embryo-
genesis, Angptl2 was detected at E3 in the hindbrain
and at E4 in neuroepithelium of the forebrain and hind-
brain and also in the heart [22]. As part of the Arp2/3
complex, ANGPTL2 interacts directly with the WAVE
(Wiskott–Aldrich syndrome protein family verprolin-
homologous protein) complex to induce actin cytoskel-
eton changes and is involved in the regulation of axon
growth [23]. Regarding haploinsufficiency prediction,
both the RVI score of −0.867014353 (10.7th percentile)
and a low HI score of 6.9 % point to ANGPTL2 haploin-
sufficiency being pathogenic.
In contrast to contiguous gene syndromes such as
Williams syndrome, several other microdeletion syn-
dromes have been shown recently to be caused mainly
by haploinsufficiency of a single responsible gene such
as MEF2C in 5q14.3 microdeletion syndrome [24] or
SHANK3 in Phelan-McDermid syndrome [25]. We were
interested to determine which scenario applies to micro-
deletion 9q33.3 syndrome. Overall, neither expression
patterns nor functional data nor the RVI and HI scores
pointed to one of the SRO genes as the main or even
single responsible gene for the 9q33.3-q34.1 microdele-
tions reported here. Consequently, we analyzed the
expression levels of RALGPS1, GARNL3, and ANGPTL2
to gain possible evidence for their haploinsufficiency.
We included STXBP1 in our expression studies in order
to investigate the possibility of a reduced expression
caused by long-range position effects of the deletion in
patient 3 which did not include STXBP1. The gene
expression studies for GARNL3, RALGPS1, ANGPTL2,
and STXBP1 on whole blood RNA of patients 1 through
5 demonstrated significantly reduced expression levels of
the SRO gene GARNL3 in all patients. The expression
level of the non-SRO gene ANGPTL2 in whole bloodRNA was too low to be analyzed. RALGPS1 expression
was reduced significantly in patients 1 through 4 but not
in patient 5 whose deletion did not encompass the gene.
STXBP1 did not show a significantly reduced expression
in patient 3, in whom STXBP1 was not deleted, thus
excluding a possible long-range position effect for her
deletion. Our expression studies did not narrow down
the causative genes by providing evidence for haploin-
sufficiency of only one of the SRO genes. Thus, we per-
formed Sanger sequencing of the SRO genes RALGPS1
and GARNL3 in more than 156 patients with ID and DD
in order to find possible evidence of loss-of-function
mutations in one of these genes as a frequent cause for
ID and DD. However, all detected variants were either
known single nucleotide polymorphisms listed in dbSNP
or had been inherited from an unaffected parent. Thus,
no causative mutations were detected and deleterious
sequence mutations in RALGPS1 or GARNL3 are appar-
ently not a common cause of ID and DD.
Conclusions
In summary, we present evidence for a novel 9q33.3
microdeletion syndrome consisting of ID, DD with pro-
nounced speech delay, muscular hypotonia, strabismus,
and incompletely penetrant microcephaly, short stature,
and seizures. The smallest region of deletion overlap
affects only two coding genes, RALGPS1 and GARNL3
and is localized in close proximity to the known ID /
epilepsy gene STXBP1. The seizure, ID, and DD pheno-
type in the deletions described here is at least partly
independent from STXBP1, as shown by microdeletion
sizes and expression studies. Follow-up studies on add-
itional patients are needed to determine if this syndrome
is caused by the deletion of only one of the candidate




Investigations were performed in accordance with the
protocols of the Declaration of Helsinki and were approved
by the Ethikkommission der Medizinischen Fakultät der
Universität Bonn (lfd. Nr. 120/99, 131/08). Consent to par-
ticipate was obtained from the parents for all participants.
The retrospective reports of the microdeletions which were
detected during routine array diagnostics did not require
ethics committee approval at the respective institutions.
Written consent for the publication of clinical photographs
was obtained from the parents for all five patients.
Array studies and verification
For patient 1, peripheral blood genomic DNA was
analyzed using an Illumina HumanOmni1-Quad array
according to the manufacturer’s instructions (Illumina,
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published previously [26, 27]. Real-time quantitative PCR
with three independent primer pairs was performed to con-
firm the deletion in the patient and to test for the presence
of the deletion in parental DNA as published previously
[26, 27]. Primer sequences are available upon request.
For patient 2 and his parents, peripheral blood gen-
omic DNA was analyzed according to manufacturer’s
instructions with Affymetrix Genome-Wide Human
SNP Arrays 6.0 (Affymetrix, Santa Clara, CA, USA) with
an average distance of 1.3 kb between neighboring
probes. Genotypes were called with Affymetrix Genotyp-
ing Console Software v3 (GTC) using the Birdseed algo-
rithm with the default calling threshold of 0.5 and a
prior size of 10,000 bases in a simultaneous analysis of
the patient-parents trio. Interpretation was originally
based on Human Genome Build 36 (NCBI).
Peripheral blood genomic DNA from patients 3 and 4
was analyzed using Agilent Human Genome CGH 44B
microarrays (Agilent, Santa Clara, CA, USA) according
to the manufacturer’s protocols. Female genomic DNA
(Promega, Madison, WI, USA) was used as reference
and quantitative PCR for verification and segregation
analyses was performed with QuantiTect SYBR Green
PCR Kits (Qiagen, Valencia, CA, USA).
Microarray analysis of genomic DNA from patient 5
was performed using the 720 K whole genome tiling Nim-
bleGen CGH array (Nimble-Gen®; Roche NimbleGen Inc,
Madison, Wisconsin, USA). Tiling array version Human
CGH 3 × 720 K WG-T v3.0 array which contains 720,000
probes with a median probe spacing of 2509 bp was
applied. The effective average resolution is approximately
50 kb for a required minimum of 10 consecutive aberrant
oligonucleotides. Labeling and hybridization of test and
reference DNA was performed according to the manufac-
turer’s protocols. Two-color scanning was performed with
an MS 200 Scanner (NimbleGen®; Roche NimbleGen Inc,
Madison, Wisconsin, USA). Microarray images were
acquired using the MS 200 software. Data extraction, ana-
lysis, and visualization were performed using the Nimble-
Scan™ version 2.5 and SignalMap™ version 1.9 software.
Verification in the proband and segregation analyses in
the parents were performed by fluorescence-in-situ
hybridization (FISH) using the locus-specific BAC clone
RP11-356B19 (9q34.11; BlueGnome, Cambridge, UK).
Sanger sequencing of SRO genes RALGPS1 and GARNL3
Mutational screening of RALGPS1 and GARNL3 by
Sanger sequencing was performed on 192 individuals
seen at the University Medical Genetics Clinics in Bonn,
96 of whom had mild ID/DD and 96 of whom had mod-
erate to severe ID/DD. This study group consisted of 66
females (34 %) and 126 males (66 %). A total of 82 indi-
viduals showed no or only negligible dysmorphisms(43 %), while 109 had dysmorphisms (57 %); of the latter
group, 40 patients also showed organ malformations
(21 %). Standard evaluation consisted of detailed clinical
investigation, conventional karyotyping, and the exclu-
sion of clinically recognizable syndromes with known
etiology. The presence of Fragile X syndrome had been
excluded in almost all patients. Previous molecular
karyotyping with Illumina microarrays (550, 610, 660 K
or Omni1-Quad) had identified no pathogenic aberra-
tions. The study was approved by the Institutional
Review Board of the University Hospital of Bonn, and
informed consent was obtained for all participants.
To target the coding regions of RALGPS1 and GARNL3
and flanking intronic sequence (at least 15 bp), primers
were designed using the online program Primer3
(http://primer3.ut.ee/). All known protein-coding RefSeq
isoforms were analyzed: NM_014636, NM_001190728,
NM_001190729 and NM_001190730 for RALGPS1,
NM_032293 and NM_001286779 for GARNL3. Sequen-
cing was performed with either genomic or whole genome
amplified DNA (REPLI-g WGA kit, Qiagen, Hilden,
Germany) of the 192 patients with ID/DD using standard
procedures. Amplicons were sequenced bi-directionally
using the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, California, USA). The
fluorescently labeled fragments were analyzed on a capillary
sequencing system (3130XL Genetic Analyzer, Applied Bio-
systems). Sequences were analyzed using SeqMan II soft-
ware (DNAStar, Madison, WI, USA). All primer sequences
as well as PCR conditions are available upon request. The
frequency in control cohorts was analyzed for all detected
variants using dbSNP build 142 and the NHLBI GO-ESP
cohort (Exome Variant Server, NHLBI GO Exome Sequen-
cing Project (ESP), http://evs.gs.washington.edu/EVS/; July
2015). The in silico tool CADD (Combined Annotation
Dependent Depletion, http://cadd.gs.washington.edu/, [28])
was employed to predict pathogenicity.
Expression analyses of RALGPS1, GARNL3, ANGPTL2, and
STXBP1
Expression analyses for RALGPS1, GARNL3, ANGPTL2,
and STXBP1 were performed for microdeletion patients
1 through 5 and five unaffected control persons. RNA of
the five patients and the five unaffected controls was
extracted from whole blood using the PAXgene Blood
system (Qiagen, Hilden, Germany). RNA was reverse
transcribed using Superscript II (Invitrogen, Carlsbad,
CA, USA). To measure expression levels, predesigned
TaqMan® gene expression assays (Applied Biosystems,
Foster City, CA, USA; Hs01115436_m1; Hs00171912_m1;
Hs01060483_m1; Hs01119036_m1) were used. The gene
expression analysis was performed in triplicate, with each
reaction containing 2 μl of cDNA template in a 10 μl reac-
tion volume, on a LightCycler® 480 Real-Time PCR
Ehret et al. Molecular Cytogenetics  (2015) 8:72 Page 13 of 14System (Roche, Mannheim, Germany). The cycling
conditions were as follows: 50 °C for 2 min, denatur-
ation at 95 °C for 10 min followed by 40 cycles at
95 °C for 15 s, and a combined annealing and extension
step at 60 °C for 60 s. Duplex reactions contained both
target (FAM) and endogenous control (VIC) probes and
primers. Two different endogenous controls (Human
B2M (beta-2-microglobulin) Endogenous Control; Human
PPIA (cyclophilin A) Endogenous Control; TaqMan®
Endogenous Controls, Applied Biosystems, Foster City,
CA, USA) were assayed in parallel and in separate duplex
reactions. Normalized results were compared to the re-
sults of five unaffected controls. Each triplicate experi-
ment was performed twice. P values were calculated using
a two-sided Wilcoxon test.Additional file
Additional file 1: Table S1. Sequencing results of GARNL3 in 192
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